Angiosartan 40 mg 28 tablets

Angiosartan 40 mg 28 tablets

Composition:

Olmesartan medoxomil 40 mg

Properties:

Antihypertensive agent, angiotensin II receptor blocker. It has a high selectivity for angiotensin II type 1 receptors (AT1), with the participation of which the main effects of angiotensin II are realized. By blocking these receptors, olmesartan medoxomil prevents and eliminates the vasoconstrictive effect of angiotensin II, causes a secondary increase in plasma renin activity by eliminating negative feedback on renin release and a direct decrease in aldosterone secretion.

In arterial hypertension, olmesartan medoxomil causes a dose-dependent, prolonged decrease in blood pressure.

There is no data on the development of arterial hypotension after taking the first dose of olmesartan medoxomil, tachyphylaxis with prolonged treatment and withdrawal syndrome.

When using olmesartan medoxomil 1 time / day, it provides an effective and mild reduction in blood pressure for 24 hours. The maximum antihypertensive effect is achieved after 8 weeks from the start of therapy, although a significant effect of lowering blood pressure is noted after 2 weeks of treatment.

Indications:

Essential arterial hypertension.

Mode of application:

– Take orally, daily. The initial dose is 10 mg / day. With insufficient effectiveness, the dose is increased to the optimum – 20 mg / day. If necessary, the dose can be increased to a maximum of 40 mg / day.

– For elderly patients, dose adjustment is not required. If it is necessary to increase the daily dose to a maximum of 40 mg / day, the increase should be carried out under careful monitoring of blood pressure.- For patients with mild or moderate renal impairment (CC 20-60 ml / min), the maximum daily dose is 20 mg.

Side effects:

• arterial hypotension, angina pectoris
• thrombocytopenia.
• vertigo, dizziness, headache, asthenic syndrome (fatigue, drowsiness, general malaise)
• bronchitis, pharyngitis, rhinitis, cough.
• diarrhea, dyspepsia, gastroenteritis, abdominal pain, nausea, vomiting, increased activity of liver enzymes.
• skin itching, rash, angioedema, allergic dermatitis, swelling of the face, urticaria.
• arthritis, back pain, bone pain, muscle cramps, myalgia, increased CPK activity.
• hematuria, urinary tract infection.
• hypertriglyceridemia, hyperuricemia, hyperkalemia, elevated serum creatinine and urea levels, peripheral edema.
• chest pain, flu-like symptoms.

Contraindications:

Obstruction of the biliary tract, pregnancy, breastfeeding, children and adolescents under 18 years of age, hypersensitivity to olmesartan medoxomil.

Warnings and Precautions:

– the use of olmesartan medoxomil is not recommended in patients with renal insufficiency and patients with impaired liver function.

– use with caution in patients with aortic or mitral valve stenosis or with obstructive hypertrophic cardiomyopathy.

– use olmesartan medoxomil with caution in patients with heart failure, kidney disease, with stenosis of the renal artery of both or a single kidney, since there is a risk of developing acute hypotension, azotemia, oliguria, acute renal failure.

– in the treatment of patients with impaired renal function, it is recommended to periodically monitor the level of potassium and creatinine in the blood serum.

– it is not recommended to use olmesartan medoxomil in patients with primary hyperaldosteronism.

-excessive decrease in blood pressure in patients with coronary artery disease and atherosclerosis of the cerebral vessels can lead to the development of myocardial infarction or ischemic stroke.

– dizziness or increased fatigue may occur, which must be taken into account when driving vehicles and engaging in potentially hazardous activities.

Storage:

Store at a temperature not exceeding 30°C

Package:

Cardboard box contains 4 blisters of 7 tablets.